Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06455605 · ClinicalTrials.gov registry record · Phase 1
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
A Phase 1 study of Recurrent Glioblastoma, IDH-Wildtype, sponsored by Darell Bigner.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06455605 is a Phase 1 study of Recurrent Glioblastoma, IDH-Wildtype that is actively recruiting participants, run by Darell Bigner. The registered enrollment target is 46 participants, above the 34-participant average among 4 other Recurrent Glioblastoma, IDH-Wildtype trials with a reported enrollment target (35% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06455605, a Phase 1 study of Recurrent Glioblastoma, IDH-Wildtype, is actively recruiting participants, sponsored by Darell Bigner.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with resected recurrent glioblastoma (rGBM) via convection enhanced delivery (CED), followed by subcutaneous cervical perilymphatic injections (CPLIs) of 2141-V11 2 and 4 weeks post infusion, then every 3 weeks for a year, and every 4-6 weeks thereafter if patients benefit from therapy.
Conditions Studied
Interventions
- DRUG D2C7-IT
- DRUG 2141 V11
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06455605
The ClinicalTrials.gov registry entry for NCT06455605 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 4 other Recurrent Glioblastoma, IDH-Wildtype trials with a reported enrollment target (35% higher). The listed sponsor is Darell Bigner, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Glioblastoma, IDH-Wildtype appearing as the primary indexed condition, and to 2 interventions - of which D2C7-IT is the first listed.
NCT06455605 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06455605 about?
NCT06455605 is a clinical study titled "D2C7-IT + 2141-V11 Combination Post-resection in rGBM". The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with resected recurrent glioblastoma (rGBM) via convection enhanced delivery (CED), followed by subcutaneous cervical perilymphatic injections (CP...
What is the current status of trial NCT06455605?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2025-03-17. Estimated completion is 2030-01-31.
What conditions does trial NCT06455605 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, IDH-Wildtype.
What interventions are being tested in trial NCT06455605?
The interventions under investigation include: D2C7-IT (DRUG), 2141 V11 (DRUG).
Who is sponsoring clinical trial NCT06455605?
This trial is sponsored by Darell Bigner, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06455605 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma, IDH-Wildtype
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
RECRUITING · Phase 1
-
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RECRUITING · Phase 1
-
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
-
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.